We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$8.3B
AUM Growth
-$82M
Cap. Flow
-$584M
Cap. Flow %
-7.04%
Top 10 Hldgs %
34.19%
Holding
170
New
23
Increased
24
Reduced
50
Closed
20

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$104M
2
CI icon
Cigna
CI
+$77.7M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$73.5M
4
MOH icon
Molina Healthcare
MOH
+$62.4M
5
CRNX
Crinetics Pharmaceuticals
CRNX
+$56.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$125M
2
BIIB icon
Biogen
BIIB
+$88.7M
3
SEM
Select Medical
SEM
+$77.6M
4
MRK icon
Merck
MRK
+$75.8M
5
FOLD
Amicus Therapeutics
FOLD
+$74.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.19%
2 Miscellaneous 1.02%
3 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
51
UnitedHealth
UNH
$344B
$49.6M 0.6%
186,500
+63,200
+51% +$16.4M
BHC icon
52
Bausch Health
BHC
$2.21B
$48.9M 0.59%
+1,903,900
New +$43.6M
CNC icon
53
Centene
CNC
$34.3B
$48.8M 0.59%
+674,800
New +$46.9M
ONC
54
BeOne Medicines Ltd
ONC
$39.2B
$48.7M 0.59%
282,500
+21,100
+8% +$3.55M
HRTX icon
55
Heron Therapeutics
HRTX
$59.9M
$47.9M 0.58%
1,514,500
+199,400
+15% +$7.43M
OBSV
56
DELISTED
ObsEva SA Ordinary Shares
OBSV
$47M 0.57%
2,605,531
– –
ASMB icon
57
Assembly Biosciences
ASMB
$590M
$45.8M 0.55%
102,781
+42,684
+71% +$20M
EHTH icon
58
eHealth
EHTH
$29.6M
$45.5M 0.55%
1,611,200
-223,500
-12% -$5.93M
ARVN icon
59
Arvinas
ARVN
$549M
$44.6M 0.54%
+2,645,865
New +$43.6M
LKFT
60
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.75B
$44M 0.53%
391,631
-95,359
-20% -$10.1M
TFX icon
61
Teleflex
TFX
$5.52B
$41.9M 0.5%
157,300
-33,100
-17% -$8.58M
PRQR icon
62
ProQR Therapeutics
PRQR
$262M
$39.4M 0.48%
2,037,875
+734,920
+56% +$7.81M
SPPI
63
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$38.1M 0.46%
+2,265,500
New +$49M
INSM icon
64
Insmed
INSM
$27.4B
$37M 0.45%
1,829,300
-1,098,591
-38% -$24.8M
XTNT icon
65
Xtant Medical Holdings
XTNT
$46M
$35.4M 0.43%
9,207,012
– –
ZLAB icon
66
Zai Lab
ZLAB
$2.76B
$34.2M 0.41%
1,753,538
+142,538
+9% +$3.09M
KALA icon
67
KALA BIO
KALA
$10.5M
$34M 0.41%
1,381
– –
AMGN icon
68
Amgen
AMGN
$206B
$31.4M 0.38%
151,600
+27,500
+22% +$5.42M
TNDM icon
69
Tandem Diabetes Care
TNDM
$1.17B
$30.6M 0.37%
714,500
-974,500
-58% -$34M
INSY
70
DELISTED
Insys Therapeutics, Inc.
INSY
$30.5M 0.37%
3,028,354
-483,190
-14% -$3.85M
RYTM icon
71
Rhythm Pharmaceuticals
RYTM
$7.05B
$30.4M 0.37%
1,041,353
-1,023,647
-50% -$32.3M
FOMX
72
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$29.8M 0.36%
5,195,330
+1,155,330
+29% +$6.61M
PFE icon
73
Pfizer
PFE
$158B
$29.5M 0.36%
704,810
-330,218
-32% -$12.7M
ABT icon
74
Abbott
ABT
$178B
$28.9M 0.35%
394,100
– –
SYBX
75
DELISTED
Synlogic
SYBX
$28.8M 0.35%
135,333
– –
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2018 Portfolio in Review

As of Q3 2018, OrbiMed held 170 positions worth $8.3B, down 0.98% from $8.38B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed withdrew a net $584M in Q3 2018, closing 20 positions and reducing 50 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $125M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, OrbiMed opened a new position in Principia Biopharma Inc. Common Stock worth $76.1M.

  • OrbiMed's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,605,713 shares worth $76.1M.
  • OrbiMed added most to Humana in Q3 2018, an estimated $104M increase.
  • OrbiMed's biggest Q3 2018 reduction was Biogen, cutting an estimated $88.7M.
  • OrbiMed fully exited Alnylam Pharmaceuticals in Q3 2018, selling an estimated $125M.
  • OrbiMed's ten largest holdings make up 34% of its $8.3B portfolio in Q3 2018.
  • OrbiMed opened 23 new positions and closed 20 in Q3 2018.
  • OrbiMed's portfolio value fell 0.98% quarter-over-quarter to $8.3B.

Based on OrbiMed's 13F filing for Q3 2018, filed 14 Nov 2018.